Literature DB >> 20013166

Erythroderma related to the administration of 99mTc-sestamibi: the first report.

Spyridoula Doukaki1, Mario Aricò, Maria Rita Bongiorno.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013166     DOI: 10.1007/s12350-009-9178-6

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  6 in total

1.  Erythema multiforme reaction to sestamibi.

Authors:  L E Thomson; K C Allman
Journal:  J Nucl Med       Date:  2001-03       Impact factor: 10.057

2.  Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.

Authors:  E B Silberstein; J Ryan
Journal:  J Nucl Med       Date:  1996-01       Impact factor: 10.057

3.  Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent.

Authors:  A Ramos-Gabatin; J A Orzel; T R Maloney; J E Murnane; R D Borchert
Journal:  J Nucl Med       Date:  1986-09       Impact factor: 10.057

4.  Anaphylactic reaction to Tc-99m sestamibi (Cardiolite) during pharmacologic myocardial perfusion imaging.

Authors:  Bilal Mujtaba; Michael Adenaike; Vamsee Yaganti; Najda Mujtaba; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

5.  Angioedema after injection of Tc-99m sestamibi tracer during adenosine nuclear stress testing.

Authors:  John N Makaryus; Amgad N Makaryus; Victor Azer; Joseph A Diamond
Journal:  J Nucl Cardiol       Date:  2008-04-16       Impact factor: 5.952

Review 6.  Undesirable events with radiopharmaceuticals.

Authors:  Ralph Santos-Oliveira
Journal:  Tohoku J Exp Med       Date:  2009-04       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.